StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3031% above fair value
$41.37−2.28 (-5.22%)

Close on Nov 20, 2026Market cap $5.84BP/E –Yield –

Arrowhead Pharmaceuticals free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Arrowhead Pharmaceuticals's free cash flow for the twelve months ending Jun 30, 2026 was -$75.11M. For fiscal 2025 it was $156.89M. The highest annual figure on record is $161.03M in fiscal 2019.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Sep 30, 2025$156.89M–
FY2024Sep 30, 2024-$604.32M–
FY2023Sep 30, 2023-$330.63M–
FY2022Sep 30, 2022-$188.91M-227.9%
FY2021Sep 30, 2021$147.75M–
FY2020Sep 30, 2020-$107.75M-166.9%
FY2019Sep 30, 2019$161.03M–
FY2018Sep 30, 2018-$48.64M–
FY2017Sep 30, 2017-$31.86M–
FY2016Sep 30, 2016-$68.29M–
FY2015Sep 30, 2015-$67.68M–
FY2014Sep 30, 2014-$37.13M–
FY2013Sep 30, 2013-$19.33M–
FY2012Sep 30, 2012-$15.82M–
FY2011Sep 30, 2011-$7.67M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026-$181.32M–
Q2 FY2026CQ1 2026Mar 31, 2026$81.88M-82.0%
Q1 FY2026CQ4 2025Dec 31, 2025$11.33M–
Q4 FY2025CQ3 2025Sep 30, 2025$13.00M–
Q3 FY2025CQ2 2025Jun 30, 2025-$157.08M–
Q2 FY2025CQ1 2025Mar 31, 2025$454.76M–
Q1 FY2025CQ4 2024Dec 31, 2024-$153.79M–
Q4 FY2024CQ3 2024Sep 30, 2024-$161.51M–
Q3 FY2024CQ2 2024Jun 30, 2024-$129.87M–
Q2 FY2024CQ1 2024Mar 31, 2024-$126.45M–
Q1 FY2024CQ4 2023Dec 31, 2023-$186.50M–
Q4 FY2023CQ3 2023Sep 30, 2023-$89.83M–
Q3 FY2023CQ2 2023Jun 30, 2023-$67.38M–
Q2 FY2023CQ1 2023Mar 31, 2023-$58.99M-201.7%
Q1 FY2023CQ4 2022Dec 31, 2022-$114.43M–
Q4 FY2022CQ3 2022Sep 30, 2022-$101.45M–
Q3 FY2022CQ2 2022Jun 30, 2022-$78.35M–
Q2 FY2022CQ1 2022Mar 31, 2022$57.98M-77.4%
Q1 FY2022CQ4 2021Dec 31, 2021-$67.09M–
Q4 FY2021CQ3 2021Sep 30, 2021-$32.23M–
Q3 FY2021CQ2 2021Jun 30, 2021-$33.54M–
Q2 FY2021CQ1 2021Mar 31, 2021$256.71M–
Q1 FY2021CQ4 2020Dec 31, 2020-$43.19M–
Q4 FY2020CQ3 2020Sep 30, 2020-$13.15M-319.8%
Q3 FY2020CQ2 2020Jun 30, 2020-$35.56M-587.0%
Q2 FY2020CQ1 2020Mar 31, 2020-$31.19M–
Q1 FY2020CQ4 2019Dec 31, 2019-$27.85M-116.6%
Q4 FY2019CQ3 2019Sep 30, 2019$5.98M–
Q3 FY2019CQ2 2019Jun 30, 2019$7.30M–
Q2 FY2019CQ1 2019Mar 31, 2019-$19.80M–
Q1 FY2019CQ4 2018Dec 31, 2018$167.55M–
Q4 FY2018CQ3 2018Sep 30, 2018-$3.39M–
Q3 FY2018CQ2 2018Jun 30, 2018-$14.61M–
Q2 FY2018CQ1 2018Mar 31, 2018-$15.82M–
Q1 FY2018CQ4 2017Dec 31, 2017-$14.83M-415.2%
Q4 FY2017CQ3 2017Sep 30, 2017-$9.31M–
Q3 FY2017CQ2 2017Jun 30, 2017-$11.57M–
Q2 FY2017CQ1 2017Mar 31, 2017-$15.68M–
Q1 FY2017CQ4 2016Dec 31, 2016$4.70M–
Q4 FY2016CQ3 2016Sep 30, 2016-$12.89M–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?